Juergen Eckhardt describes how this strategic impact investing arm works within Bayer, the types of investments they look for and have...

Madeleine gives her take on data from Caribou, Summit, Daiichi Sankyo, GSK, Abbvie, and more.

Paul Rennert talks about the first four patients who have been dosed in Aleta's clinical trial, as well as previewing targets such as...

From McCormick Place, Jacob Plieth previews key data from Merus, Summit, Iovance, Caribou, AstraZeneca, GSK, Gilead, and more.

From a pre-ASCO event in Chicago, John Flavin describes how Portal invests in startups while giving them fully equipped lab space to work...

Laura Chico discusses the biotech pullback of late, and comments on Biogen, Aerovate, Viridian, and Ovid.

Matt Phipps gives his take on biotech and discusses #ATS2024 data, Amgen and Keros' obesity programs, recent acquisitions by GenMab and...

Doug Edgeton describes the growth that has taken place since North Carolina Biotechnology Center was founded four decades ago, and what...

Joining us from their lab space in Raleigh, Executive Director Josh Sommer and CSO Dan Freed introduce us to chordoma and describe the...

Hatteras Venture Partners' Clay Thorp describes the growth of North Carolina's biotech industry during his firm's 20+ years of...

Chris McCarthy describes how investors are anticipating upcoming binary events and how they have been talking about broader market issues.

Roberto Bellini introduces us to his new investment firm and looks back on lessons learned from selling BELLUS to GSK.

Noël Brown shares his thoughts on the IPO market and its pipeline, following-on offerings, and takaways from the RBC Capital Markets...

Brian Abrahams previews the conference, shares his take on biotech, and offers some themes to watch throughout the remainder of the year.

Emily Walsh Martin covers regulatory comments from FDA's Peter Marks, scientific updates on prime and base editing, and more.

TJ Cradick gives us a preview of which abstracts and technologies to watch this year, including the latest in gene editing methods and...

An early adopter and researcher of AI, Noam Auslander shares her opinion of the benefits of AI but also guardrails that should be...

He explains how machine learning has allowed bit.bio to model which transcription factor combinations are needed to create a desired cell...

CIC Partner Michael Anstey describes the firm's history and investment approach, lists some current investments, and offers advice for...

Kathryn Chapman has held many roles in town and is an expert on everything Cambridge's life sciences ecosystem has to offer.